Xvivo Perfusion AB (publ) (XVIVOS.XC)
- Previous Close
266.50 - Open
273.40 - Bid 300.50 x --
- Ask 306.00 x --
- Day's Range
266.50 - 266.50 - 52 Week Range
263.80 - 503.50 - Volume
1,014 - Avg. Volume
22 - Market Cap (intraday)
8.801B - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
48.99 - EPS (TTM)
5.44 - Earnings Date Apr 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.
www.xvivogroup.comRecent News: XVIVOS.XC
View MorePerformance Overview: XVIVOS.XC
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XVIVOS.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XVIVOS.XC
View MoreValuation Measures
Market Cap
8.80B
Enterprise Value
8.42B
Trailing P/E
48.99
Forward P/E
49.02
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.26
Price/Book (mrq)
3.89
Enterprise Value/Revenue
10.24
Enterprise Value/EBITDA
29.14
Financial Highlights
Profitability and Income Statement
Profit Margin
20.94%
Return on Assets (ttm)
2.43%
Return on Equity (ttm)
8.40%
Revenue (ttm)
822.41M
Net Income Avi to Common (ttm)
172.18M
Diluted EPS (ttm)
5.44
Balance Sheet and Cash Flow
Total Cash (mrq)
415.52M
Total Debt/Equity (mrq)
1.58%
Levered Free Cash Flow (ttm)
-138.93M